「by」の検索結果
76件：16～20件目を表示
-
that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this "Product") from Ministry of Health, Labour and Welfare. Th...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf -
eutical Co., Ltd. Launch and Distribution of “MIEr for ImageFS” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for ImageFS” in Japan. MIEr for ImageFS...
https://www.senju.co.jp/system/files/content_news/2024-11/ENG_20241126_0.pdf -
ical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for dry-eye analysis in Japan as an option of RE...
https://www.senju.co.jp/system/files/content_news/2024-09/ENG_20240906.pdf -
ical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of RET-700 in Japan, effective immediately (medical device a...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240726_0.pdf -
学会发表 | 研究与开发 | 千寿制药株式会社
orado, United States of America Motugivatrep suppresses the expression of proinflammatory mediators by inhibiting TRPV1 activation mediated by hyperosmotic and inflammatory stimuli in human corneal ep...
https://www.senju.co.jp/chinese/rd/society/